Lytix Biopharma AS (OSL:LYTIX)
Norway · Delayed Price · Currency is NOK 10.40
+0.10 (0.97%)
Apr 1, 2026, 12:02 PM CET
Lytix Biopharma AS Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
799.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 11.13M | 7.14M | 178.98% |
| Dec 31, 2023 | 3.99M | -7.04M | -63.82% |
| Dec 31, 2022 | 11.03M | -8.28M | -42.87% |
| Dec 31, 2021 | 19.31M | 15.23M | 373.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ArcticZymes Technologies ASA | 118.21M |
| Aqua Bio Technology ASA | 101.51M |
| Arctic Bioscience AS | 45.90M |
| Oncoinvent ASA | 20.00M |
| SoftOx Solutions AS | 15.58M |
| PCI Biotech Holding ASA | 4.69M |
| Nykode Therapeutics AS | 4.57M |
| Thor Medical ASA | 839.00K |